You might also like
No business description found.
- Given the forecasted acceleration in sequential growth from 9% to 11% in Q4, what specific market conditions or sales initiatives are driving this expectation, and how will you mitigate risks associated with seasonal slowdowns?
- With the long-term $5 billion sales target for CAPLYTA, can you detail the pricing assumptions made and the expected revenue split between bipolar depression and MDD, while addressing potential regulatory or market headwinds?
- Considering the strong 38% year-over-year prescription growth, how will you measure the success of your recent primary care sales force expansion, and what corrective actions are planned if these initiatives do not yield the expected incremental uptake?
- Regarding the long-acting injectable (LAI) program, what definitive milestones have you set to evaluate the success of testing four different formulations given the historically low LAI penetration rates, and what is your contingency strategy if these targets are not met?
- For the ITI-1284 program in GAD, how do you plan to leverage the deuterated formulation to improve the safety profile—particularly regarding somnolence—and what are your regulatory and commercialization plans should the Phase II results prove positive?
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
CAPLYTA for the treatment of schizophrenia and bipolar depression competes with a branded product marketed by this company. | |
Otsuka Pharmaceutical | CAPLYTA for the treatment of schizophrenia and bipolar depression competes with a branded product marketed by this company. |
CAPLYTA for the treatment of schizophrenia and bipolar depression competes with a branded product marketed by this company. | |
CAPLYTA for the treatment of schizophrenia and bipolar depression competes with a branded product marketed by this company. | |
CAPLYTA for the treatment of schizophrenia and bipolar depression competes with a branded product marketed by this company. |
Recent press releases and 8-K filings for ITCI.
Intra-Cellular Therapies, Inc. Becomes a Johnson & Johnson Subsidiary
$ITCIM&A
Delisting/Listing Issues
Board Change
- Merger Completion: On April 2, 2025, the merger was finalized, converting each common share to a cash consideration of $132.00 per share.
- Change in Control: As a result of the transaction, the company became a wholly owned subsidiary of Johnson & Johnson, with approximately $14.6 billion in consideration paid to its stockholders.
- Listing Update: The company notified Nasdaq to halt trading and initiated procedures to delist its shares and deregister under the Exchange Act.
- Governance Amendments: The company’s certificate of incorporation and bylaws were amended and restated, leading to a board reorganization with incoming directors from Merger Sub.
Apr 2, 2025, 12:00 AM
Intra-Cellular Therapies, Inc. Approves Merger Agreement
$ITCIM&A
Proxy Vote Outcomes
- Special meeting held on March 27, 2025: The company approved its Merger Agreement with Johnson & Johnson, where a special meeting of stockholders was convened.
- Merger vote details: Approximately 73.31% of outstanding shares were represented, leading to the successful adoption of both the Merger Agreement and related proposals, with the transaction expected to close on or around April 2, 2025.
Mar 27, 2025, 12:00 AM
Intra-Cellular Therapies Files 8-K on Merger and Legal Developments
$ITCIM&A
Legal Proceedings
- The 8-K announces the filing of a Proxy Statement and an upcoming special meeting on March 27, 2025, related to the merger with Johnson & Johnson, with stockholder eligibility as of February 13, 2025.
- Multiple litigation actions have been initiated by stockholders, including the Morgan, O’Neill, and Drulias complaints, alleging misrepresentations in the Proxy Statement disclosures.
- Supplemental disclosures include detailed valuation analyses by Centerview Partners and Jefferies, comparing ITI’s estimated per share equity value (approximately $102.90 to $127.70) to the merger consideration of $132.00 per share.
Mar 18, 2025, 12:00 AM